{"id":139262,"date":"2026-07-03T12:38:19","date_gmt":"2026-07-03T07:08:19","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=139262"},"modified":"2026-07-03T12:38:21","modified_gmt":"2026-07-03T07:08:21","slug":"alivus-life-sciences-q1-results-2027-preview","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/","title":{"rendered":"Alivus Life Sciences Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Alivus Life Sciences CMP Rs.1,179. Market cap Rs.14,232 Cr. PE 25.2. 12-month target Rs.1,190-1,344.<\/em><\/p>\n<p>Alivus Life Sciences Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with <a href=\"https:\/\/univest.in\/stocks\/alivus\/glenmark-life-sciences-ltd-share-price-today\">Alivus Life Sciences<\/a> shares trading at Rs.1,179 against a market capitalisation of Rs.14,232 Cr and a price-to-earnings multiple of 25.2. As an industrials and capital goods name on the NSE and BSE, Alivus Life Sciences enters the Alivus Life Sciences Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.<\/p>\n<p>Quarterly financials for Alivus Life Sciences are not yet fully available on Univest&#8217;s data partners for this cycle; investors should track Screener.in and the NSE\/BSE filings directly for the Alivus Life Sciences Q1 Results FY27 result date and cross-check any figures before making investment decisions.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=alivus-life-sciences-q1-fy27\"><strong>Get Free Investment Predictions and Alivus Life Sciences Research at Univest<\/strong><\/a><\/p>\n<p>Alivus Life Sciences (NSE: ALIVUS) operates in the industrials and capital goods space and is tracked on Univest under its NSE and BSE listings ahead of the Alivus Life Sciences Q1 Results FY27 season, forming the base against which the Alivus Life Sciences Q1 Results FY27 estimates in this article are built. This Alivus Life Sciences Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company&#8217;s own disclosures.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#Alivus_Life_Sciences_Q1_FY27_Estimates\" title=\"Alivus Life Sciences Q1 FY27 Estimates\">Alivus Life Sciences Q1 FY27 Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#Key_Catalysts_to_Watch\" title=\"Key Catalysts to Watch\">Key Catalysts to Watch<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#1_Order_Book_Execution\" title=\"1. Order Book Execution\">1. Order Book Execution<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#2_Capex_Revival_in_User_Industries\" title=\"2. Capex Revival in User Industries\">2. Capex Revival in User Industries<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#3_Operating_Leverage\" title=\"3. Operating Leverage\">3. Operating Leverage<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#Key_Risks_to_the_Alivus_Life_Sciences_Q1_Results_FY27_Outlook\" title=\"Key Risks to the Alivus Life Sciences Q1 Results FY27 Outlook\">Key Risks to the Alivus Life Sciences Q1 Results FY27 Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#Q4_FY26_Performance_Context\" title=\"Q4 FY26 Performance Context\">Q4 FY26 Performance Context<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#Technical_Analysis_Ahead_of_Alivus_Life_Sciences_Q1_Results_FY27\" title=\"Technical Analysis Ahead of Alivus Life Sciences Q1 Results FY27\">Technical Analysis Ahead of Alivus Life Sciences Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#Share_Price_Target_Based_on_the_Alivus_Life_Sciences_Q1_Results_FY27_Outlook\" title=\"Share Price Target Based on the Alivus Life Sciences Q1 Results FY27 Outlook\">Share Price Target Based on the Alivus Life Sciences Q1 Results FY27 Outlook<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#3-6_Month_Target\" title=\"3-6 Month Target\">3-6 Month Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#12-Month_Target\" title=\"12-Month Target\">12-Month Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#FY27-28_Outlook\" title=\"FY27-28 Outlook\">FY27-28 Outlook<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#What_to_Watch_in_the_Alivus_Life_Sciences_Q1_Results_FY27_Print\" title=\"What to Watch in the Alivus Life Sciences Q1 Results FY27 Print\">What to Watch in the Alivus Life Sciences Q1 Results FY27 Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#Conclusion_on_Alivus_Life_Sciences_Q1_Results_FY27\" title=\"Conclusion on Alivus Life Sciences Q1 Results FY27\">Conclusion on Alivus Life Sciences Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#FAQs_on_Alivus_Life_Sciences_Q1_Results_FY27\" title=\"FAQs on Alivus Life Sciences Q1 Results FY27\">FAQs on Alivus Life Sciences Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#When_are_Alivus_Life_Sciences_Q1_FY27_results_expected\" title=\"When are Alivus Life Sciences Q1 FY27 results expected?\">When are Alivus Life Sciences Q1 FY27 results expected?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#What_is_the_Alivus_Life_Sciences_Q1_FY27_revenue_estimate\" title=\"What is the Alivus Life Sciences Q1 FY27 revenue estimate?\">What is the Alivus Life Sciences Q1 FY27 revenue estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#What_is_the_Alivus_Life_Sciences_share_price_target\" title=\"What is the Alivus Life Sciences share price target?\">What is the Alivus Life Sciences share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#Is_Alivus_Life_Sciences_a_good_buy_before_Q1_FY27_results\" title=\"Is Alivus Life Sciences a good buy before Q1 FY27 results?\">Is Alivus Life Sciences a good buy before Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#What_should_investors_watch_in_Alivus_Life_Sciencess_Q1_FY27_results\" title=\"What should investors watch in Alivus Life Sciences&#8217;s Q1 FY27 results?\">What should investors watch in Alivus Life Sciences&#8217;s Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-q1-results-2027-preview\/#Where_can_I_track_Alivus_Life_Sciences_share_price_live\" title=\"Where can I track Alivus Life Sciences share price live?\">Where can I track Alivus Life Sciences share price live?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Alivus_Life_Sciences_Q1_FY27_Estimates\"><\/span><strong>Alivus Life Sciences Q1 FY27 Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse;\">\n<thead>\n<tr style=\"background: #F0F2F5;\">\n<th style=\"padding: 8px; text-align: left; border: 1px solid #DDD;\">Metric<\/th>\n<th style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px; border: 1px solid #DDD;\">CMP<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">Rs.1,179<\/td>\n<\/tr>\n<tr style=\"background: #FFFFFF;\">\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Market Cap<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">Rs.14,232 Cr<\/td>\n<\/tr>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Results Date<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">July-August 2026 (indicative)<\/td>\n<\/tr>\n<tr style=\"background: #FFFFFF;\">\n<td style=\"padding: 8px; border: 1px solid #DDD;\">12-Month Target (Uniresearch Estimate)<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">Rs.1,190-1,344<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Univest, a SEBI-Registered Investment Advisor, Tracks Alivus Life Sciences Ahead of Q1 FY27 Results<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Catalysts_to_Watch\"><\/span><strong>Key Catalysts to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Order_Book_Execution\"><\/span><strong>1. Order Book Execution<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Healthy order book execution translating into revenue recognition for the quarter is one of the primary variables that analysts are tracking ahead of Alivus Life Sciences&#8217;s Q1 FY27 results and FY27 guidance. The market&#8217;s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Alivus Life Sciences share price target or faces renewed pressure.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Capex_Revival_in_User_Industries\"><\/span><strong>2. Capex Revival in User Industries<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Capex revival in core user industries supporting fresh order inflows is one of the primary variables that analysts are tracking ahead of Alivus Life Sciences&#8217;s Q1 FY27 results and FY27 guidance. The market&#8217;s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Alivus Life Sciences share price target or faces renewed pressure.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Operating_Leverage\"><\/span><strong>3. Operating Leverage<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Operating leverage on higher volumes aiding margin expansion versus last year is one of the primary variables that analysts are tracking ahead of Alivus Life Sciences&#8217;s Q1 FY27 results and FY27 guidance. The market&#8217;s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Alivus Life Sciences share price target or faces renewed pressure.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Alivus Life Sciences&#8217;s live price and Q1 FY27 result updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Alivus_Life_Sciences_Q1_Results_FY27_Outlook\"><\/span><strong>Key Risks to the Alivus Life Sciences Q1 Results FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Order execution delays pushing revenue recognition to later quarters.<\/li>\n<li>Raw material and input cost inflation pressuring margins.<\/li>\n<li>Slower capex recovery in key end-user industries affecting order inflows.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Q4_FY26_Performance_Context\"><\/span><strong>Q4 FY26 Performance Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Detailed Q4 FY26 financials for Alivus Life Sciences were not available from Univest&#8217;s data partners at the time of writing. Investors should check Screener.in or the company&#8217;s exchange filings for the latest verified numbers before the Q1 FY27 results.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Analysis_Ahead_of_Alivus_Life_Sciences_Q1_Results_FY27\"><\/span><strong>Technical Analysis Ahead of Alivus Life Sciences Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alivus Life Sciences shares last traded at Rs.1,179. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Share_Price_Target_Based_on_the_Alivus_Life_Sciences_Q1_Results_FY27_Outlook\"><\/span><strong>Share Price Target Based on the Alivus Life Sciences Q1 Results FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"3-6_Month_Target\"><\/span><strong>3-6 Month Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Over a 3-6 month horizon, the Alivus Life Sciences Q1 Results FY27 trailing-growth framework points to a range of Rs.1,156-1,251 for Alivus Life Sciences, contingent on the Alivus Life Sciences Q1 Results FY27 print matching or beating the trailing growth trend.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12-Month_Target\"><\/span><strong>12-Month Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month target (Uniresearch estimate) tied to this Alivus Life Sciences Q1 Results FY27 view for Alivus Life Sciences works out to Rs.1,190-1,344, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Alivus Life Sciences Q1 Results FY27, not a formal Buy or Sell call.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FY27-28_Outlook\"><\/span><strong>FY27-28 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Alivus Life Sciences Q1 Results FY27 analysis would put Alivus Life Sciences in a Rs.1,256-1,469 range, though this is sensitive to sector-wide demand, cost trends and any change in the company&#8217;s competitive position.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_in_the_Alivus_Life_Sciences_Q1_Results_FY27_Print\"><\/span><strong>What to Watch in the Alivus Life Sciences Q1 Results FY27 Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Revenue and PAT versus the Alivus Life Sciences Q1 Results FY27 estimate range in this preview.<\/li>\n<li>Management commentary on FY27 growth guidance and margin trajectory relevant to the Alivus Life Sciences Q1 Results FY27 narrative.<\/li>\n<li>Healthy order book execution translating into revenue recognition for the quarter<\/li>\n<li>Order execution delays pushing revenue recognition to later quarters<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_on_Alivus_Life_Sciences_Q1_Results_FY27\"><\/span><strong>Conclusion on Alivus Life Sciences Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alivus Life Sciences enters the Q1 FY27 results season trading at Rs.1,179, with the 12-month Uniresearch target range of Rs.1,190-1,344 reflecting a tracking stance. Investors tracking the Alivus Life Sciences Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Alivus_Life_Sciences_Q1_Results_FY27\"><\/span><strong>FAQs on Alivus Life Sciences Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_are_Alivus_Life_Sciences_Q1_FY27_results_expected\"><\/span><strong>When are Alivus Life Sciences Q1 FY27 results expected?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. Alivus Life Sciences&#8217;s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Alivus_Life_Sciences_Q1_FY27_revenue_estimate\"><\/span><strong>What is the Alivus Life Sciences Q1 FY27 revenue estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. Detailed quarterly estimates are not available for Alivus Life Sciences at this time; check Screener.in or the company&#8217;s exchange filings for verified numbers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Alivus_Life_Sciences_share_price_target\"><\/span><strong>What is the Alivus Life Sciences share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. The 12-month Uniresearch estimate for Alivus Life Sciences share price target is Rs.1,190-1,344, based on trailing growth and current valuation multiples.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Alivus_Life_Sciences_a_good_buy_before_Q1_FY27_results\"><\/span><strong>Is Alivus Life Sciences a good buy before Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. Alivus Life Sciences is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_watch_in_Alivus_Life_Sciencess_Q1_FY27_results\"><\/span><strong>What should investors watch in Alivus Life Sciences&#8217;s Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and healthy order book execution translating into revenue recognition for the quarter.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_Alivus_Life_Sciences_share_price_live\"><\/span><strong>Where can I track Alivus Life Sciences share price live?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. Alivus Life Sciences share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"When are Alivus Life Sciences Q1 FY27 results expected?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Alivus Life Sciences's Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.\"}},{\"@type\":\"Question\",\"name\":\"What is the Alivus Life Sciences Q1 FY27 revenue estimate?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Detailed quarterly estimates are not available for Alivus Life Sciences at this time; check Screener.in or the company's exchange filings for verified numbers.\"}},{\"@type\":\"Question\",\"name\":\"What is the Alivus Life Sciences share price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The 12-month Uniresearch estimate for Alivus Life Sciences share price target is Rs.1,190-1,344, based on trailing growth and current valuation multiples.\"}},{\"@type\":\"Question\",\"name\":\"Is Alivus Life Sciences a good buy before Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Alivus Life Sciences is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.\"}},{\"@type\":\"Question\",\"name\":\"What should investors watch in Alivus Life Sciences's Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and healthy order book execution translating into revenue recognition for the quarter.\"}},{\"@type\":\"Question\",\"name\":\"Where can I track Alivus Life Sciences share price live?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Alivus Life Sciences share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alivus Life Sciences Q1 Results FY27 preview: revenue and PAT estimates, results date, key catalysts, risks and share price target.<\/p>\n","protected":false},"author":35,"featured_media":139302,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-139262","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1783062507:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["80"],"rank_math_focus_keyword":["Alivus Life Sciences Q1"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Alivus Life Sciences Q1 FY27 Results Preview"],"rank_math_description":["Alivus Life Sciences Q1 Results FY27 preview: revenue estimate, PAT outlook, results date, key catalysts, risks and share price target based on trailing growth analysis."],"_thumbnail_id":["139302"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["23244"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/Alivus-Life-Sciences-Q1-Results-FY27.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/139262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=139262"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/139262\/revisions"}],"predecessor-version":[{"id":139303,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/139262\/revisions\/139303"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/139302"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=139262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=139262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=139262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}